[View Original Text]

Korean company AIDOT Inc. (CEO Jaehoon Jeong) announced on the 6th that it has obtained registration approval from AGEMED, the registration authority for pharmaceuticals and medical 

devices in Bolivia.

Bolivia is the country with the highest incidence of cervical cancer in Latin America. Among the total female population over 15 years old in Bolivia, there are 4.01 million people, and the 

annual incidence and mortality rates of cervical cancer are 1,986 and 1,054, respectively, with a fatality rate of 53%. The incidence rate of cervical cancer per 100,000 people is 36.6, 

making it a serious disease that ranks first among female cancers in Bolivia.

AGEMED, which has now been registered, is an organization responsible for registration and regulation in the medical field in Bolivia. It plays a crucial role in verifying the quality and safety of

 pharmaceuticals and medical devices and regulating them, protecting the health of the Bolivian population.

A representative from AIDOT's global sales and marketing department stated, "Through this registration approval in Bolivia, we have laid the foundation for entering the Central and South

 American markets in earnest. Currently, we are actively communicating with Brazil, Argentina, and other neighboring Central and South American countries. We expect another significant 

leap. We are also pleased to be able to provide an environment for efficiently conducting cervical cancer screenings, which have the highest mortality rate among female cancers in Bolivia."

AIDOT has been continuously pursuing overseas registration approvals since last year, receiving recognition for reliability and quality in the medical device industry. This can be attributed to

 AIDOT's innovative product lineup and rigorous quality management system.

AIDOT stated that it will continue to develop and innovate through ongoing research and development, aiming to become a company that commercializes practical medical AI solutions 

overseas.

Korean Economic TV / 06th. July. 2023 / Reporter Junsik Park